Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ligand Pharma ( (LGND) ) has shared an announcement.
On August 14, 2025, Ligand Pharmaceuticals completed a private offering of $460 million in convertible senior notes due 2030, including an additional $60 million purchased by initial buyers. The notes, which are unsecured and bear a 0.75% interest rate, are part of Ligand’s strategy to manage potential stock dilution and fund corporate purposes, including stock repurchases and convertible note hedge transactions. These financial maneuvers are expected to impact Ligand’s stock market activity and provide flexibility in managing its capital structure.
The most recent analyst rating on (LGND) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.
Spark’s Take on LGND Stock
According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.
Ligand Pharma’s overall stock score is driven by strong earnings call results and positive corporate events, indicating strategic growth potential. However, financial performance and valuation concerns, such as declining revenue and a negative P/E ratio, weigh down the score. Technical analysis shows bullish momentum, but caution is advised due to overbought signals.
To see Spark’s full report on LGND stock, click here.
More about Ligand Pharma
Ligand Pharmaceuticals Incorporated operates in the pharmaceutical industry, focusing on drug discovery and development. The company is known for its innovative technologies and partnerships with other pharmaceutical companies to develop and commercialize medicines.
Average Trading Volume: 199,257
Technical Sentiment Signal: Buy
Current Market Cap: $2.99B
For a thorough assessment of LGND stock, go to TipRanks’ Stock Analysis page.